Arabic Arabic English English French French German German
dark

Sanofi Goes All-In on Parkinson’s with “Groundbreaking” ABL Bio Deal

Sanofi will pay ABL $75 million upfront, and the latter is eligible to receive as much as $985 million down the line as development, regulatory, and commercialization milestones are met.  Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

40% of eligible population have had boosters; 28 community cases; 2 deaths; 31 people in hospital; two in ICU

Next Post

The unexpected benefits of fat in type 2 diabetes

Related Posts
Total
0
Share